From Casetext: Smarter Legal Research

In re Generic Pharm. Pricing Antitrust Litig.

United States District Court, E.D. Pennsylvania
Feb 14, 2024
MDL 2724 (E.D. Pa. Feb. 14, 2024)

Opinion

MDL 2724 16-MD-2724

02-14-2024

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION THIS DOCUMENT RELATES TO ALL ACTIONS


ORDER

CYNTHIA M. RUFE, J.

AND NOW, this 14th day of February 2024, upon consideration of Special Master Lawrence F. Stengel's Third Formal Report and Recommendation (“Third R&R”), filed on January 12, 2024 [MDL Doc. No. 2773], and no timely objections having been filed thereto by any party, it is hereby ORDERED that the Third R&R is APPROVED and ADOPTED. It is further ORDERED that Plaintiff State of Louisiana shall comply with RFP 68 by February 26, 2024, or the Court will entertain a motion from Defendants for sanctions.

It is so ORDERED.

BY THE COURT:


Summaries of

In re Generic Pharm. Pricing Antitrust Litig.

United States District Court, E.D. Pennsylvania
Feb 14, 2024
MDL 2724 (E.D. Pa. Feb. 14, 2024)
Case details for

In re Generic Pharm. Pricing Antitrust Litig.

Case Details

Full title:IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION THIS DOCUMENT…

Court:United States District Court, E.D. Pennsylvania

Date published: Feb 14, 2024

Citations

MDL 2724 (E.D. Pa. Feb. 14, 2024)